Cargando…
METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS
The genetic contribution of rare pathogenic germline variation in cancer patients without a family history remains unclear. We sought to characterize the prevalence, spectrum, and clinical significance of pathogenic germline variation in cancer predisposition genes (CPGs) in pediatric brain tumor pa...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260081/ http://dx.doi.org/10.1093/neuonc/noad073.126 |
_version_ | 1785057784165826560 |
---|---|
author | McQuaid, Shelly W Kaufman, Rebecca Corbett, Ryan J Vaksman, Zalman Bornhorst, Miriam Brown, Miguel A Guo, Yiran S Zhu, Yuankun Heath, Allison P Storm, Phillip B Resnick, Adam C Waanders, Angela J Cole, Kristina A Rokita, Jo Lynne Macfarland, Suzanne Diskin, Sharon J |
author_facet | McQuaid, Shelly W Kaufman, Rebecca Corbett, Ryan J Vaksman, Zalman Bornhorst, Miriam Brown, Miguel A Guo, Yiran S Zhu, Yuankun Heath, Allison P Storm, Phillip B Resnick, Adam C Waanders, Angela J Cole, Kristina A Rokita, Jo Lynne Macfarland, Suzanne Diskin, Sharon J |
author_sort | McQuaid, Shelly W |
collection | PubMed |
description | The genetic contribution of rare pathogenic germline variation in cancer patients without a family history remains unclear. We sought to characterize the prevalence, spectrum, and clinical significance of pathogenic germline variation in cancer predisposition genes (CPGs) in pediatric brain tumor patients. Paired tumor and normal whole genome or exome sequencing was performed for 838 patients in the Pediatric Brain Tumor Atlas (PBTA). Rare variants in 196 CPGs were annotated as pathogenic (P) or likely pathogenic (LP) in an automated manner consistent with American College of Medical Genetics criteria and reviewed by an interdisciplinary panel. To assess enrichment, the frequency of CPG P-LP variants in cases was compared to the gnomAD v3.1 cancer-free control cohort (n=74,023). Second hit, mutational signature, and gene set enrichment analyses (GSEA) were performed on matched tumor sequencing to characterize differences in patients with and without germline P-LP variants in DNA repair genes. We observed 178 germline CPG P-LP variants in 163 PBTA patients (19.5%). CPG P-LP variants were most prevalent among Neurofibroma plexiform patients (64.3%), and NF1 and TSC2 harbored the most significant P-LP variant burden compared to controls (OR=69.5, p=2.4E-23, CI=34.6-137 and OR=357, p=1.1E-14, CI=71-3669, respectively). DNA repair gene P-LP variants were enriched in cases compared to controls (OR=4.4, p=8.3E-30). Patients harboring mismatch repair (MMR) gene P-LP variants exhibited significantly higher tumor-associated MMR-deficiency mutational signature exposures (p<0.05) and DNA repair GSEA scores relative to other patients (p=0.04). Second hit SNVs in tumors were identified in four patients with P-LP germline variants in NF1 (n=2), APC (n=1), and SUFU (n=1). Germline P-LP variants are enriched in PBTA patients, and DNA repair variants are predictive of repair-deficiency signatures in tumor samples. Our work emphasizes the need for germline sequencing to inform patient care. |
format | Online Article Text |
id | pubmed-10260081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102600812023-06-13 METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS McQuaid, Shelly W Kaufman, Rebecca Corbett, Ryan J Vaksman, Zalman Bornhorst, Miriam Brown, Miguel A Guo, Yiran S Zhu, Yuankun Heath, Allison P Storm, Phillip B Resnick, Adam C Waanders, Angela J Cole, Kristina A Rokita, Jo Lynne Macfarland, Suzanne Diskin, Sharon J Neuro Oncol Final Category: Genomics/Epigenomics/Metabolomics - METB The genetic contribution of rare pathogenic germline variation in cancer patients without a family history remains unclear. We sought to characterize the prevalence, spectrum, and clinical significance of pathogenic germline variation in cancer predisposition genes (CPGs) in pediatric brain tumor patients. Paired tumor and normal whole genome or exome sequencing was performed for 838 patients in the Pediatric Brain Tumor Atlas (PBTA). Rare variants in 196 CPGs were annotated as pathogenic (P) or likely pathogenic (LP) in an automated manner consistent with American College of Medical Genetics criteria and reviewed by an interdisciplinary panel. To assess enrichment, the frequency of CPG P-LP variants in cases was compared to the gnomAD v3.1 cancer-free control cohort (n=74,023). Second hit, mutational signature, and gene set enrichment analyses (GSEA) were performed on matched tumor sequencing to characterize differences in patients with and without germline P-LP variants in DNA repair genes. We observed 178 germline CPG P-LP variants in 163 PBTA patients (19.5%). CPG P-LP variants were most prevalent among Neurofibroma plexiform patients (64.3%), and NF1 and TSC2 harbored the most significant P-LP variant burden compared to controls (OR=69.5, p=2.4E-23, CI=34.6-137 and OR=357, p=1.1E-14, CI=71-3669, respectively). DNA repair gene P-LP variants were enriched in cases compared to controls (OR=4.4, p=8.3E-30). Patients harboring mismatch repair (MMR) gene P-LP variants exhibited significantly higher tumor-associated MMR-deficiency mutational signature exposures (p<0.05) and DNA repair GSEA scores relative to other patients (p=0.04). Second hit SNVs in tumors were identified in four patients with P-LP germline variants in NF1 (n=2), APC (n=1), and SUFU (n=1). Germline P-LP variants are enriched in PBTA patients, and DNA repair variants are predictive of repair-deficiency signatures in tumor samples. Our work emphasizes the need for germline sequencing to inform patient care. Oxford University Press 2023-06-12 /pmc/articles/PMC10260081/ http://dx.doi.org/10.1093/neuonc/noad073.126 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Final Category: Genomics/Epigenomics/Metabolomics - METB McQuaid, Shelly W Kaufman, Rebecca Corbett, Ryan J Vaksman, Zalman Bornhorst, Miriam Brown, Miguel A Guo, Yiran S Zhu, Yuankun Heath, Allison P Storm, Phillip B Resnick, Adam C Waanders, Angela J Cole, Kristina A Rokita, Jo Lynne Macfarland, Suzanne Diskin, Sharon J METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS |
title | METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS |
title_full | METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS |
title_fullStr | METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS |
title_full_unstemmed | METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS |
title_short | METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS |
title_sort | metb-09. germline pathogenic variants in 838 pediatric brain tumor patients |
topic | Final Category: Genomics/Epigenomics/Metabolomics - METB |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260081/ http://dx.doi.org/10.1093/neuonc/noad073.126 |
work_keys_str_mv | AT mcquaidshellyw metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT kaufmanrebecca metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT corbettryanj metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT vaksmanzalman metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT bornhorstmiriam metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT brownmiguela metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT guoyirans metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT zhuyuankun metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT heathallisonp metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT stormphillipb metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT resnickadamc metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT waandersangelaj metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT colekristinaa metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT rokitajolynne metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT macfarlandsuzanne metb09germlinepathogenicvariantsin838pediatricbraintumorpatients AT diskinsharonj metb09germlinepathogenicvariantsin838pediatricbraintumorpatients |